Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2025)

Camp4 Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $78.3 million for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity rose 42.52% year-over-year to $78.3 million; the TTM value through Sep 2025 reached $78.3 million, up 2.62%, while the annual FY2024 figure was $78.3 million, 42.52% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $78.3 million at Camp4 Therapeutics, up from $21.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $78.3 million in Q4 2024 and bottomed at $21.4 million in Q3 2024.